Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 7,413 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Dyskeratosis Congenita, Aplastic Anemia
Interventions: Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions: Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review, Microarray Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting; Other · Genetic
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Proximal Muscle Strength, Proximal Muscle Lengthening
Interventions: myofascial release, blood flow restriction; Other · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Basal Cell Carcinoma
Interventions: Two photon fluorescence microscopy imaging; Device
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Victor, New York

Conditions: Knee Injuries, Joint Surface Knee Lesions
Interventions: Marketed Product - MP01, Surgical Standard of Care; Device · Procedure
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Lung Tumor, Lung Cancer
Interventions: Microdevice loaded with 19 chemotherapeutic agents; Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Localized Prostate Cancer
Interventions: Robotic Waterjet Treatment; Device
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Glenview, Illinois • New York, New York

Conditions: Severe Facial Deformity
Interventions: Facial Allograft Transplantation; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liposuction, Cellulite, Cellulite Reduction, Fibrosis; Skin
Interventions: AVELI; Device
Lead sponsor: Total Definer Research Group; Other
Eligibility: 18 Years to 60 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Interventions: Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure; Drug · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer
Interventions: Tumor Sample, Serum Sample; Procedure
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer
Interventions: Muse MRgFUS System; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Peripheral Artery Disease, Critical Limb Ischemia
Interventions: Temsirolimus, Saline placebo; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: Houma, Louisiana • Dallas, Texas

Conditions: Lymphedema, Secondary, Lymphedema of Upper Limb
Interventions: PhysioTouch, Manual Lymph Drainage (MLD); Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Histiocytic Disorder
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Year and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases
Interventions: Data and Specimen Collection; Genetic
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Soft Tissue Inflammation
Interventions: Standard Hydrocolloid Dressing, Silver Hydrocolloid Dressing; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Month to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer, Metastatic Cancer
Interventions: Treatment Planning using the DIBH Technique; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Abscess
Interventions: oral trimethoprim/sulfamethoxazole, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 90 Days to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: ClariCore System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Hemophilia A, Hemophilia B
Interventions: marstacimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Vismodegib; Biological · Procedure · Drug
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Hypertension, Cancer, Lung Disease, Cardiothoracic Surgery
Interventions: Nesiritide (Natrecor), Right Heart Catheterization; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions: Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening

Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy

A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used for the Treatment of Joint Surface Lesions of the Knee

Microdevice for Evaluating Drug Response in Site in Lung Lesions

PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

Face Transplantation for Treatment of Severe Facial Deformity

Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device

Clinical and Molecular Characteristics of Histiocytic Disorders

Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement

Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

ClariCore System Used in Transperineal Prostate Biopsy

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Natrecor in Pulmonary Hypertension

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival